40 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2019-04-24T00:57:06Z-
dc.date.available2019-04-24T00:57:06Z-
dc.date.issued2016-08-
dc.identifier.citationBIOMATERIALS SCIENCE, v. 4, No. 9, Page. 1340-1350en_US
dc.identifier.issn2047-4830-
dc.identifier.issn2047-4849-
dc.identifier.urihttp://pubs.rsc.org/-/content/articlehtml/2016/bm/c6bm00376a-
dc.identifier.urihttp://repository.hanyang.ac.kr/handle/20.500.11754/102651-
dc.description.abstractCancer remains a leading cause of death. A combination of anticancer agents can effectively kill cancer through multiple pathways; however, improvements to their delivery are needed. Hence, docetaxel and cisplatin-loaded liquid crystalline nanoparticles with folic acid were prepared for effective and targeted anticancer therapy. Notably, hydroxypropyl-beta-cyclodextrin/cisplatin complexes in 0.9% NaCl solution were used for the prevention of possible aquation of cisplatin, which would otherwise lead to severe adverse effects. The optimized nanoparticles exhibited small particle size, high drug loading capacity (>90%), and controlled drug release profiles. In vitro cell cytotoxicity assays demonstrated that the optimized nanoparticles were taken up by folate receptor-expressing cells to a greater extent than non-folate expressing cells, which is attributable to folate-specific endocytosis of the optimized nanoparticles. Enhanced expression of apoptotic markers (Bax, p21, and cleaved caspase-3) along with enhanced anti-migration effects in MDA-MB-231 cells following treatment suggests that the optimized nanoparticles provide an effective treatment for metastatic breast cancer. These results were further supported by in vivo findings obtained for a MDA-MB-231 tumor xenograft model. Altogether, the optimized nanoparticles may potentially be developed as an effective treatment modality for folate-targeted metastatic breast cancer treatment.en_US
dc.description.sponsorshipThis research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806). This work was also supported by the Medical Research Center Program (2015R1A5A2009124) through the NRF funded by MSIP.en_US
dc.language.isoen_USen_US
dc.publisherROYAL SOC CHEMISTRYen_US
dc.subjectDRUG-DELIVERYen_US
dc.subjectFOLATE-RECEPTORen_US
dc.subjectCOPOLYMER NANOPARTICLESen_US
dc.subjectPHOTODYNAMIC THERAPYen_US
dc.subjectDNA-DAMAGEen_US
dc.subjectCELL-LINESen_US
dc.subjectIN-VITROen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectRESISTANCEen_US
dc.subjectCYCLODEXTRINSen_US
dc.titleLiquid crystalline nanoparticles encapsulating cisplatin and docetaxel combination for targeted therapy of breast canceren_US
dc.typeArticleen_US
dc.relation.no9-
dc.relation.volume4-
dc.identifier.doi10.1039/c6bm00376a-
dc.relation.page1340-1350-
dc.relation.journalBIOMATERIALS SCIENCE-
dc.contributor.googleauthorThapa, RK-
dc.contributor.googleauthorChoi, JY-
dc.contributor.googleauthorGupta, B-
dc.contributor.googleauthorRamasamy, T-
dc.contributor.googleauthorPoudel, BK-
dc.contributor.googleauthorKu, SK-
dc.contributor.googleauthorYoun, YS-
dc.contributor.googleauthorChoi, HG-
dc.contributor.googleauthorYong, CS-
dc.contributor.googleauthorKim, JO-
dc.relation.code2016005610-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE